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OBJECTIVES The main objective of this study was to assess if the benefits of biventricular (BiV) pacing
observed during the crossover phase were sustained over 12 months.
BACKGROUND MUltisite STimulation In Cardiomyopathies (MUSTIC) is a randomized controlled study
intended to evaluate the effects of BiV pacing in patients with New York Heart Association
(NYHA) class III heart failure and intraventricular conduction delay.
METHODS Of 131 patients included, 42/67 in sinus rhythm (SR) and 33/64 in atrial fibrillation (AF)
were followed up longitudinally at 9 and 12 months by 6-min walked distance, peak oxygen
uptake (peak VO2), quality of life by the Minnesota score, NYHA class, echocardiography,
and left ventricular ejection fraction by radionuclide technique.
RESULTS At 12 months, all SR and 88% of AF patients were programmed to BiV pacing. Compared
with baseline, the 6-min walked distance increased by 20% (SR) (p  0.0001) and 17% (AF)
(p  0.004); the peak VO2 by 11% (SR) and 9% (AF); quality of life improved by 36% (SR)
(p  0.0001) and 32% (AF) (p  0.002); NYHA class improved by 25% (SR) (p  0.0001)
and 27% (AF) (p 0.0001). The ejection fraction improved by 5% (SR) and 4% (AF). Mitral
regurgitation decreased by 45% (SR) and 50% (AF).
CONCLUSIONS The clinical benefits of BiV pacing appeared to be significantly maintained over a 12-month
follow-up period. (J Am Coll Cardiol 2002;40:111–8) © 2002 by the American College of
Cardiology Foundation
Despite recent advances in drug treatment for heart failure
(HF) (1–3), many patients are not sufficiently improved by
drug treatment. Previously, these patients could be offered
only heart transplantation or a cardiac assist. In recent years,
biventricular (BiV) pacing has emerged as a promising
therapeutic addition in a subset of these patients.
It is estimated that 30% of patients with severe HF have
intraventricular conduction disturbances characterized elec-
trically by wide QRS complexes and characterized mechan-
ically by a discoordinated ventricular contraction and relax-
ation pattern (4). This electromechanical delay in
ventricular activation may be partially overcome by BiV
pacing. Acute hemodynamic studies and uncontrolled stud-
ies of permanent implants in these patients suggest that BiV
pacing significantly improves hemodynamics, symptoms,
exercise tolerance, and quality of life (5–8). The MUltisite
STimulation In Cardiomyopathies (MUSTIC) study is a
randomized trial designed to assess the clinical efficacy of
BiV pacing in this subset of HF patients. We have previ-
ously reported substantial symptomatic relief from the
crossover phase of this study (9,10). These improvements
were, however, observed over a three-month period. The
long-term effects of BiV pacing remain to be determined.
The aim of the present study was to assess the one-year
results of the MUSTIC study.
METHODS
Patient selection. All patients had chronic severe HF due
to idiopathic or ischemic left ventricular (LV) systolic
dysfunction, with an ejection fraction35% as measured by
radionuclides and an LV end-diastolic diameter60 mm at
echocardiography. Patients were stabilized in New York
Heart Association (NYHA) functional class III HF for at
least one month before inclusion and were receiving opti-
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mized drug treatment that included at least diuretics and
angiotensin-converting enzyme (ACE) inhibitors at the
maximum tolerated dose. The 6-min walked distance had to
450 m. Patients with sinus rhythm (SR) did not have a
conventional indication for pacing and a QRS duration
150 ms. The atrial fibrillation (AF) patients had persistent
(3 months) AF requiring permanent ventricular pacing
due to slow ventricular rate, either spontaneous or induced
by atrioventricular (AV) node junction ablation. For these,
a paced QRS duration 200 ms during right ventricular
(RV) pacing was required. Exclusion criteria and pacemaker
implantation technique have been described previously
(9,10).
Study design. This European multicenter trial involved 16
centers in six countries (9). The study was approved by the
local ethics committee of all centers, and all patients gave
their written informed consent before inclusion. Inclusion
began in March 1998 and was completed 15 months later.
The study began with a single-blind crossover comparison
of three months each of BiV pacing and inactive pacing (SR
group) or BiV compared with right univentricular rate
adaptive ventricular inhibited pacing (VVIR) pacing (AF
group) followed by a longitudinal follow-up. At the end of
the crossover phase, patients were asked which of the
three-month periods they preferred and were programmed
accordingly. If no preference was expressed, the program-
ming was made according to the physician’s judgment.
Thereafter, the patients were followed up every three
months. This article is a 12-month intra-patient long-term
comparison for patients programmed to BiV pacing at the
end of the crossover phase. Thus, baseline and 12-month
follow-up parameters are compared. Data concerning the
crossover phase in BiV pacing at six months and the
follow-up phase at nine months are reported for descriptive
purposes.
Evaluated parameters. Patients were evaluated with the
6-min walked distance, the peak VO2 by cardio-pulmonary
exercise test, quality of life, NYHA class, systolic and
diastolic blood pressure (BP), body-weight, 12-lead surface
electrocardiogram (ECG), 24-h Holter monitoring and
Doppler echocardiography. Heart rate (HR) was calculated
from the ECG, and the systolic and diastolic BPs were
measured by a cuff manometer after 10 min of supine rest.
The QRS duration was measured during BiV pacing and
during spontaneous rhythm (SR group) or RV-VVIR with
a basic rate of 70 beats/min (AF group). The LV ejection
fraction by 99mTc and the cardiothoracic (CT) ratio by chest
X-ray were calculated at baseline and after 12 months.
The 6-min walk test was carried out according to
Guyatt’s recommendation (11). Quality of life was evaluated
with the Minnesota-Living with Heart Failure question-
naire (12). The higher the score, the poorer the quality of
life. Hospitalizations, mortality, and pacemaker complica-
tions were monitored at each follow-up and classified by an
independent safety committee.
Statistical analysis. Values are presented as mean  SD.
The calculation of the sample size based solely on the
crossover phase of the study has previously been described
(9). All statistical tests are intra-patient comparisons inde-
pendently performed for each group between parameters
evaluated at 12 months compared with randomization (SR
group) or baseline (AF group). To correct for incomplete
follow-up data, the values in each individual at the BiV
crossover phase at months 6, 9, and 12 were always related
to the same patients at baseline. The Student paired t test
was performed for paired comparisons. In order to adjust for
multiple analysis comparisons, the Bonferroni method has
been applied to the four main efficacy criteria defined in the
study protocol (6-min walked distance, peak VO2, quality-
of-life score, and NYHA class). Therefore, the threshold of
significance was set at 0.0125 for individual comparisons to
comply with a global significance level of 0.05.
All analyses for mortality and hospitalizations were based
on the intention-to-treat principle, thus encompassing the
total of 131 patients in the SR and AF groups included.
RESULTS
The study profile is shown in Figure 1. A total of 131
patients consented to participate in the study. Eighty-seven
patients completed both crossover phases: 48 in the SR-
group and 41 in the AF group. At that time, significantly
more patients in both groups preferred BiV pacing: 41/48 or
85% in the SR group (p  0.001) and 35/41 or 85% (p 
0.001) in the AF group.
In the SR group, five additional patients were pro-
grammed to BiV pacing according to the physician’s judg-
ment, whereas two preferred the period corresponding to
VVI 40, and another was erroneously programmed to the
VVI 40 mode and programmed correctly back to BiV
pacing at the nine-month follow-up.
In the AF group, four patients preferred the period
corresponding to RV-VVIR and were programmed accord-
ingly. Thus, at the 9- and 12-month follow-ups, all patients in
Abbreviations and Acronyms
ACE  angiotensin-converting enzyme
AF  atrial fibrillation
AV  atrioventricular
BiV  biventricular
BP  blood pressure
CT  cardiothoracic
HF  heart failure
HR  heart rate
LV  left ventricle/ventricular
MUSTIC  MUltisite STimulation In
Cardiomyopathies
NYHA  New York Heart Association
RV  right ventricle/ventricular
SR  sinus rhythm
VVIR  rate adaptive ventricular inhibited pacing
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SR and 86 (88%) in the AF group were programmed to BiV
pacing. The reason for reprogramming was deterioration in
the heart failure condition.
Pacemaker performance. One case of transient elevation
of LV threshold was seen. No other complications related to
the LV lead were found between the 6- and 12-month
follow-up. Thus, at the end of the 12-month follow-up, all
LV leads were fully functional.
Clinical characteristics of patients at the time of inclusion.
The clinical characteristics at the time of inclusion are
presented in Table 1. Sixty-three percent of the patients in
the AF group had undergone a previous AV junction
ablation. Moreover, 36% of AF patients had a previous
pacemaker before entering the study.
QRS duration over time. The QRS duration during BiV
pacing and during spontaneous rhythm (SR group) or right
ventricular pacing (VVIR) with a basic rate of 70 beats/min
(AF group) is given in Figure 2. As evidence that BiV
pacing had been delivered, a significant decrease in QRS
width of 8% to 14% in the SR group and 14% to 24% in the
AF group was seen at all times of observation. No signs of
an incremental decrease by time were observed in either of
the two groups. The duration of the spontaneous QRS
remained unchanged over time.
Six-min walked distance, peak VO2, quality of life, and
NYHA class. The results of the 6-min walked distance,
peak VO2, and quality of life are given in Table 2. To
correct for incomplete follow-up data, the values in each
individual at the BiV crossover phase at months 6, 9, and 12
were always compared with the same number of patients at
baseline.
In the SR group by the 12-month follow-up, a mean
improvement in 6-min walked distance of 70 meters, or
20% compared with baseline, was found with highly statis-
tically significant improvements between baseline and the
6-, 9-, and 12-month follow-ups. There was, however, no
evidence of an incremental improvement over the 12-month
follow-up period. In the AF group, the mean improvement
at 12 months was 55 meters or 17%.
The peak VO2 at 12 months had increased by
1.7 ml/min/kg or 11% (p  NS) in the SR group and
1.1 ml/kg/min or 9% (p  NS) in the AF group compared
with baseline. At the same time, there was mean reduction
in the Minnesota score of 17 points or 36% in the SR group
and of 14 points or 32% in the AF group. The NYHA class
improved by 0.7 in the SR group and 0.8 in the AF group.
Thus, maintained benefits without incremental change were
observed in the 12-month follow-up.
Figure 1. Study profile. Number of patients active in the study at each follow-up between inclusion and the 12 months in the sinus rhythm (left side) and
atrial fibrillation (right side) groups. The reasons for study exits during the crossover phase of the study have been published elsewhere (9). BiV 
biventricular; ICD  implantable cardioverter defibrillator; VVIR  rate adaptive ventricular inhibited pacing.
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Systolic and diastolic BP, body weight, and HR. For
both groups of patients, the systolic and diastolic BP and
pulse pressure remained unchanged over time. Body weight
did not change. The HR decreased in the SR group from
75  13 at baseline to 71  12 at 6 months, 68  11 at 9
months, and 70  10 at 12 months, with no statistically
progressive change observed over time.
Echocardiographic data, ejection fraction, and CT ratio.
The LV echocardiographic data over time is presented in
Table 3. For the SR group, improvements in LV dimen-
sions had already been observed after the crossover phase in
BiV pacing, with sustained effects over time. Mitral regur-
gitation had decreased markedly by 24% at 6 months, by
39% at 9 months, and by 45% at 12 months. Diastolic filling
Table 1. Baseline Characteristics
Demography and
Clinical Characteristics
Sinus Rhythm Group
(n  67)
Atrial Fibrillation Group
(n  64)
Mean age (yrs) 63  10 65  9
Gender (male/female) 50 (75%)/17 (25%) 52 (81%)/12 (19%)
NYHA III 67 (100%) 64 (100%)
Ischemic/Nonischemic 25 (37%)/42 (63%) 17 (27%)/47 (73%)
Drug treatment
Ace inhibitor or AII blocker 64 (96%) 64 (100%)
Diuretics 63 (94%) 63 (98%)
Cardiac glycoside 32 (48%) 36 (57%)
Beta-blockers 19 (28%) 14 (22%)
Spironolactone 15 (22%) 10 (15%)
Amiodarone 21 (31%) 14 (22%)
Mean measurements
LVEF (%) 22  8 26  10
LVEDD (mm) 73  10 68  7
MR area (cm2) 7.4  6.8 10.5  13.7
DFT (ms) 376  134 349  95
ECG measurements
Heart rate (beats/min) 75  13 74  5
QRS duration (ms) 176  19 206  19
LBBB 58 (87%) NA
PR interval (ms) 215  43 NA
6-min walked distance (m) 320  97 328  80
Peak VO2 (ml/min/kg) 13.6  3.8 12.7  3.9
SBP (mm Hg) 117  14 120  21
DBP (mm Hg) 74  9 72  12
Weight (kg) 79  19 76  14
DBP  diastolic blood pressure; DFT  diastolic filling time; LBBB  left bundle branch block; LVEDD  left ventricular
end-diastolic diameter; LVEF  left ventricular ejection fraction; MR  mitral regurgitation; NA  not applicable; SBP 
systolic blood pressure.
Figure 2. The QRS duration over time. (A) Solid lines represent values during spontaneous rhythm and dotted lines those during biventricular (BiV)
pacing in the sinus rhythm group. (B) For the atrial fibrillation group, solid lines represent values during right ventricular pacing at a rate of 70 beats/min
and dotted lines those during BiV pacing. CO  cardiac output; M3  three months; M6  six months; M9  nine months; M12  12 months;
NoP  inactive pacing; RV  right ventricle.
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time increased by 13% to 27%. For the AF group, no
changes in LV dimensions were observed. Mitral regurgi-
tation decreased by 35% at 9 months and 50% by 12 months
compared with baseline values.
Mortality. The intention-to-treat analysis of the one-year
survival rate in the global population of 131 patients was
83% (85% in SR and 81% in AF). Of 23 deaths, nine were
sudden (SR, n  5; AF, n  4). There were nine deaths
from HF (SR, n  4; AF, n  5): two from stroke (1 in
each group), and three from non-cardiovascular causes (2
from cancer and 1 from infection). No deaths were attrib-
uted to the pacemaker system.
Hospitalizations for HF. To compensate for the twice-as-
long time spent in BiV pacing compared with VVI 40 (SR
group) or RV-VVIR pacing (AF group) in the study, we
calculated the individual monthly rate of HF-related hos-
pitalizations (Table 4). During this 12-month follow-up,
there were seven times fewer hospitalizations for HF during
BiV pacing in the SR group and four times fewer in the AF
group.
DISCUSSION
This is the first study to show favorable one-year results in
exercise tolerance and quality of life by BiV pacing in
patients with severe HF and intraventricular conduction
disturbances. In addition, improvements in LV function
and a decrease in HF-related hospitalizations were found. A
placebo effect of pacemaker implantation has previously
been shown in patients treated with AV synchronous pacing
for hypertrophic obstructive cardiomyopathy (13). Such a
placebo effect wanes over the course of time. Therefore, the
present sustained benefits can be presumed to be actual
treatment effects of BiV pacing.
Patient material. The patients in this study were selected
for having stable NYHA III HF despite optimized medical
treatment. This implied the use of ACE inhibitors or
equivalents at an optimal dose but not beta-blockers or
aldosterone antagonists, because the results from the beta-
blocker trials (14) and the Randomized Aldactone Evalua-
tion Study (RALES) (3) trial were not available at the time
Table 2. The Evolution of the 6-min Walked Distance, Peak VO2, QoL and NYHA Class at M6, M9 and M12
Sinus Rhythm Group
Randomization M6 M9 M12
6-min walked distance (m) 354  92 (n  43) 396  104 (n  43)
346  96 (n  38) 411  113 (n  38)
348  98 (n  38) 418  112 (n  38)
p  0.0001
Peak VO2 (ml/kg/min) 14.2  4.6 (n  41) 15.5  4.6 (n  41) NA
14.9  4.7 (n  32) 16.6  3.6 (n  32)
p  NS
QoL score (0–105) 47  22 (n  46) 31  22 (n  46)
45  21 (n  41) 30  20 (n  41)
47  23 (n  41) 30  22 (n  41)
p  0.0001
NYHA (I–IV) 2.8  0.4 (n  46) 2.1  0.5 (n  46)
2.8  0.4 (n  40) 2.1  0.4 (n  40)
2.8  0.4 (n  41) 2.1  0.5 (n  41)
p  0.0001
Atrial Fibrillation Group
Randomization M6 M9 M12
6-min walked distance (m) 338  87 (n  37) 363  101 (n  37)
320  82 (n  27) 368  97 (n  27)
315  80 (n  27) 370  87 (n  27)
p  0.004
Peak VO2 (ml/kg/min) 12.8  4.7 (n  37) 14.3  4.1 (n  37) NA
12.8  3.6 (n  24) 13.9  3.5 (n  24)
p  NS
QoL score (0–105) 44  22 (n  40) 34  20 (n  40)
45  22 (n  31) 34  22 (n  31)
45  23 (n  28) 31  17 (n  28)
p  0.002
NYHA (I–IV) 3.0  0 (n  38) 2.3  0.5 (n  38)
3.0  0 (n  29) 2.1  0.4 (n  29)
3.0  0 (n  28) 2.2  0.5 (n  28)
p  0.0001
M6  six months; M9  nine months; M12  12 months; NA  not applicable; NS  nonsignificant (p  0.0125 Bonferroni adjustment); NYHA  New York Heart
Association; QoL  quality of life.
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the study was planned. The predominant cause of HF in the
MUSTIC trial was dilated cardiomyopathy, contrasting
with what has been reported in the drug trials but in
agreement with other studies on BiV pacing (5,8,15). The
mean Minnesota quality-of-life scores were 51  20 and
46 22 in the SR and AF groups, respectively, correspond-
ing with what can be expected in NYHA class III patients
(16).
Effect of therapy delivery on electrical and mechanical
remodeling. As evidence that pacing therapy had been
delivered and was partly successful in reducing the intraven-
tricular conduction delay, the QRS duration during BiV
pacing decreased significantly in both groups of patients.
However, in concordance with previous observations, no
signs of a progressive decrease in the spontaneous QRS
duration were seen, indicating a lack of electrical remodeling
by BiV pacing (17). By contrast, the LV ejection fraction
increased in both patient groups; mitral regurgitation de-
Table 3. Echocardiographic Data and Ejection Fraction for the Sinus Rhythm Group and the Atrial Fibrillation Group at M6, M9
and M12
Sinus Rhythm Group
Randomization M6 M9 M12
LVEDD (mm) 74  9 (n  46) 69  11 (n  46)
73  9 (n  42) 68  10 (n  42)
74  10 (n  40) 67  12 (n  40)
LVESD (mm) 64  10 (n  46) 58  12 (n  46)
64  10 (n  42) 57  11 (n  42)
63  10 (n  40) 58  12 (n  40)
MR area (cm2) 7.4  6.8 (n  44) 5.6  8.3 (n  44)
8.0  7.8 (n  39) 4.9  4.6 (n  39)
7.8  7.8 (n  39) 4.3  4.0 (n  39)
DFT (ms) 376  134 (n  44) 430  137 (n  44)
372  132 (n  42) 471  154 (n  42)
375  136 (n  40) 425  129 (n  40)
LVEF (%) radionuclides NA
NA
24.5  7.8 (n  26) 30.0  12.1 (n  26)
CT ratio 0.60  0.07 (n  41) 0.60  0.07 (n  41)
0.59  0.07 (n  34) 0.56  0.06 (n  34)
0.60  0.07 (n  36) 0.56  0.06 (n  36)
Atrial Fibrillation Group
Randomization M6 M9 M12
LVEDD (mm) NA
69  8 (n  28) 68  10 (n  28)
70  9 (n  28) 68  8 (n  28)
LVESD (mm) NA
59  9 (n  28) 56  11 (n  28)
60  10 (n  28) 58  9 (n  28)
MR area (cm2) NA
10.2  13.7 (n  27) 6.4  6.2 (n  27)
10.8  13.7 (n  26) 5.4  3.9 (n  26)
DFT (ms) NA
349  95 (n  27) 357  133 (n  27)
346  99 (n  24) 405  143 (n  24)
LVEF (%) radionuclides NA
NA
26.7  6.9 (n  19) 30.4  7.8 (n  19)
CT ratio 0.61  0.07 (n  36) 0.60  0.07 (n  36)
0.61  0.07 (n  26) 0.60  0.06 (n  26)
0.61  0.07 (n  27) 0.60  0.07 (n  27)
CT  cardiothoracic; DFT  diastolic filling time; LVEDD  left ventricular end-diastolic diameter; LVEF  left ventricular ejection fraction; LVESD  left ventricular end
systolic diameter; MR  mitral regurgitation; M6  six months; M9  nine months; M12  12 months; NA  not applicable.
Table 4. Hospitalizations for Heart Failure
SR Group AF Group
Pacing Mode VVI40 BiV RV-VVIR 70 BiV
Hospitalization (no.) 22 11 28 9
Total time spent
in pacing mode
(no. of months)
156 475 198 218
Hospitalization per month 0.14 0.02 0.14 0.04
No statistical analysis performed.
AF  atrial fibrillation; BiV  biventricular; RV  right ventricle; SR  sinus
rhythm; VVI40  ventricular inhibited pacing at a rate of 40 bpm; VVIR  rate
adapted ventricular inhibited pacing.
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creased, and in the SR group, LV dimensions were reduced,
indicating a potential mechanical reverse remodeling by BiV
pacing. Gras et al. (15) previously reported a 5% to 10%
increase in ejection fraction as measured by echocardio-
graphic technique in an uncontrolled study. Reduction in
LV dimensions by BiV pacing was recently reported by Lau
et al. (18) in a small patient material. This is the first study
to show improvements in LV global ejection fraction by BiV
pacing using a reliable technique. One might speculate that
an increased systolic function could be hazardous because
studies of drugs with inotropic effect have been linked to a
worse survival (19). An increased contractility could be
explained by an increase in sympathetic nerve activity.
However, in this study of an electromechanical intervention,
the significant decrease in HR as by the normal sinus node
during BiV pacing could be interpreted as an indirect sign of
a lesser activation of the sympathetic nervous system. Our
study results yield indices suggesting that BiV pacing
improves contractility without increasing sympathetic nerve
activity.
Long-term clinical improvements. The magnitude of im-
provements in exercise tolerance and quality of life by BiV
pacing in addition to ACE inhibitors in the present study
was greater than what has previously been observed in drug
trials with similar patients studied over a similar duration
(16,20). Importantly, these benefits were maintained over a
12-month follow-up and reinforced in the AF group. In
general, however, the results for patients with AF were less
impressive. Overall, the magnitude of improvements agree
with the one-year results from a similar study (21). More-
over, the recently reported Multicentre InSync Randomized
Clinical Evaluation trial—a six-month parallel study com-
paring BiV pacing with conventional drug treatment (22)—
reported improvements of similar degree in similar patients,
however, with a QRS width criterion less strict than ours.
Hospitalizations and mortality. Costs for hospital care
have been found to constitute the major cost for society in
HF management (23). A pilot study has indicated a lesser
need for hospital care after the implantation of BiV pacing
(24). This observation was confirmed in the present study in
which we found seven times less need for hospital care for
HF in the SR group and four times less in the AF group
compared with the crossover phase in inactive or RV-VVIR
pacing. The overall one-year survival rate was 85%, corre-
sponding to what has recently been reported in drug trials
for similar patients (3). The present study was, however, not
designed as a mortality study, and the question of whether
BiV pacing favorably affects morbidity and mortality re-
mains to be answered by larger ongoing studies such as the
Controlled Resynchronization in Heart Failure study and
the Comparison of Medical Therapy Pacing and Defibril-
lation in Chronic Heart Failure trials (25).
Study limitations. The calculation of sample size was
made for the crossover phase and not for the long-term
follow-up of the study. Although the echocardiography
results thus have to be interpreted with caution, they all
indicate a long-term benefit of BiV pacing. Ongoing stud-
ies, adequately powered to detect long-term differences, will
add the final proof of long-term benefits by this treatment
modality.
Conclusions. This is the first study to report favorable
one-year results of BiV pacing in patients with severe HF
and major intraventricular conduction disturbances in either
SR or AF. We found a significant sustained benefit in
exercise tolerance quality of life from BiV over a 12-month
follow-up period. A reduction in mitral regurgitation and an
improvement in ejection fraction were also observed. Hos-
pitalizations for HF were fewer during BiV pacing.
Whether these favorable results translate into an improved
survival remains to be established.
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